What is Charles River?
Charles River is a prominent entity dedicated to expediting the development of critical drugs, chemicals, and medical devices. Their comprehensive suite of products and services spans the entire lifecycle of product development, from initial research and discovery through safety assessment, manufacturing, and eventual commercialization. By leveraging an expansive end-to-end portfolio, global operational capacity, and seasoned scientific and regulatory expertise, Charles River employs an integrated approach designed to maximize speed and instill confidence in bringing vital innovations to market.
How much funding has Charles River raised?
Charles River has raised a total of $258M across 2 funding rounds:
Stock Offering
$224M
Unspecified
$34M
Stock Issuance/Offering (2000): $224M, investors not publicly disclosed
Unspecified (2011): $34M led by National Institutes of Health
Key Investors in Charles River
National Institutes of Health
The National Institutes of Health (NIH) is a primary agency of the U.S. Department of Health and Human Services, responsible for biomedical and health-related research, providing crucial backing for scientific advancement.
What's next for Charles River?
The recent major strategic investment signals a period of accelerated growth and expansion for Charles River. This capital will likely be deployed to enhance its research and development capabilities, broaden its service offerings, and potentially expand its global footprint. The company's focus on supporting clients from basic research to commercialization positions it to capitalize on emerging trends in biotechnology and pharmaceutical development, further solidifying its market leadership.
See full Charles River company page
